Results 221 to 230 of about 16,537,601 (356)

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Increasing client participation in family planning consultations: "Smart Patient" coaching in Indonesia

, 2002
Young Ki, Fitri Putjuk, Endang Basuki, Adrienne Kols   +3 more
openalex   +2 more sources

Patient Participation in Health Service Costs [PDF]

, 2005
Iga Rudawska
openalex   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers [PDF]

, 2006
Heidbüchel Hein, Nicole Panhuyzen-Goedkoop, Domenico Corrado, Ellen Hoffmann, A. Biffi, Pietro Delise, Carina Blomström‐Lundqvist, Luc Vanhees, Per IvarHoff, Uwe Dorwarth, Antonio Pelliccia   +10 more
openalex   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Patient participation in decision‐making on the introduction of home respiratory care: who does not participate?

, 2003
Päivi M. Hämäläinen, Marja‐Leena Perälä, Tuija Poussa, Marjaana Pelkonen   +3 more
openalex   +1 more source

Recommendations for participation in competitive and leisure sports in patients with congenital heart disease: a consensus document [PDF]

, 2006
Asle Hirth, T. Reybrouck, Birna Bjarnason‐Wehrens, Wolfgang Lawrenz, A Hoffmann   +4 more
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

CMS proposed revisions to conditions to participation: Part I—patient safety requirements [PDF]

, 2006
Ralph Levy
openalex   +1 more source